## MDT: Medtronic plc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.3% below STRENGTH zone (3.0-6.0%); PEG 2.32 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($97.66)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 9, Bearish: 0)

**1. Medtronic announces FDA clearance of Hugo™ robotic-assisted surgery system for urologic surgical procedures**
- Source: Medtronic | 20251203T213254 | Bullish | Relevance: 99%
- Medtronic announced that its Hugo™ robotic-assisted surgery (RAS) system has received FDA clearance for urologic surgical procedures in the U.S. This clearance introduces a new choice for hospitals and surgeons looking to expand their robotic surgery programs and enhance patient access to minimally invasive care. The Hugo RAS system features a modular design, an integrated digital ecosystem with the Touch Surgery™ platform, and a differentiated partnership approach, supporting urologic procedures like prostatectomy, nephrectomy, and cystectomy.

**2. Medtronic announces cash dividend for third quarter of fiscal year 2026**
- Source: KWKT - FOX 44 | 20251204T210800 | Bullish | Relevance: 99%
-  Medtronic plc's board of directors approved a cash dividend of $0.71 per ordinary share for the third quarter of fiscal year 2026, consistent with their dividend increase announcement in May 2025. This marks the 48th consecutive year the company, a constituent of the S&P 500 Dividend Aristocrats index, has increased its annual dividend payment. The dividend is payable on January 16, 2026, to shareholders of record as of December 26, 2025.

**3. Medtronic PLC (NYSE:MDT) Declares Quarterly Dividend of $0.71**
- Source: MarketBeat | 20251205T125116 | Bullish | Relevance: 99%
-  Medtronic PLC (NYSE:MDT) has declared a quarterly dividend of $0.71 per share, payable on January 16, 2026, to shareholders of record on December 26, 2025. This dividend represents a 2.8% yield and is supported by Medtronic's 49 consecutive years of dividend increases and a payout ratio around 47.2%. The medical technology company recently beat Q3 earnings expectations with $1.36 EPS and $8.96B revenue, and provided FY2026 EPS guidance of $5.62–$5.66.

**4. Medtronic earns expanded FDA nod for deep brain stim**
- Source: MassDevice | 20251205T120653 | Bullish | Relevance: 99%
-  Medtronic (NYSE: MDT) has announced that the FDA approved expanded labeling for its deep brain stimulation (DBS) offering, shifting from humanitarian device exemption (HDE) status to full effectiveness labeling. This approval extends the use of Medtronic's DBS technology to include dystonia, a movement disorder, making it the third-most common movement disorder in the U.S. The Percept platform, which delivers DBS, now includes adaptive capabilities with BrainSense technology, offering tailored, non-destructive treatment for adult and pediatric patients with various forms of dystonia.

**5. Medtronic gets FDA nod for Hugo surgical robot in urologic procedures**
- Source: MassDevice | 20251203T215935 | Bullish | Relevance: 99%
- Medtronic's Hugo robotic-assisted surgery system has received FDA clearance for urologic procedures in the U.S., marking its first U.S. approval for a soft-tissue surgical robot. The modular platform, which is already used internationally, aims to provide U.S. surgeons with a versatile tool to expand robotic surgery programs. Medtronic plans to pursue indications for general and gynecologic surgical procedures in the future.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Barclays | $111 | $109 | +2% |
| 2025-11-20 | Truist Securiti | $110 | $103 | +7% |
| 2025-11-19 | Morgan Stanley | $117 | $107 | +9% |
| 2025-11-19 | RBC Capital | $118 | $111 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Barclays | main | Overweight |
| 2025-11-20 | Truist Securiti | main | Hold |
| 2025-11-19 | Morgan Stanley | main | Overweight |
| 2025-11-19 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.20M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.4% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 9 raises (avg +11%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.32 elevated, pricing in significant growth expectations. Forward P/E 16.6x stretched relative to 8% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment positive (9 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $127.8B |
| Beta | 0.72 |
| 52W Range | $79.29 - $106.33 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.32 |
| Forward P/E | 16.6 |
| Current P/E | 17.9 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.9% to -3.3% (-2.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.3pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.28% (CS: 20) | Weak |
| RSI_14 | 58.5 | Neutral |
| MACD Histogram | -0.04 | Bearish |
| vs SMA20 | 1.016x | Above |
| vs SMA50 | 1.049x | Above |
| vs SMA200 | 1.117x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $101.36
- **Stop Loss:** $97.66 (3.7% risk)
- **Target:** $105.06 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 135
- **Position Value:** $13,683.60
- **Portfolio %:** 13.68%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*